|1.||Pruneau, D: 6 articles (01/2006 - 01/2000)|
|2.||Pruneau, Didier: 5 articles (05/2006 - 08/2002)|
|3.||Baethmann, A: 4 articles (01/2006 - 01/2000)|
|4.||Plesnila, N: 4 articles (01/2006 - 01/2000)|
|5.||Ivashkova, Yulia: 3 articles (05/2003 - 08/2002)|
|6.||Asa, Ilia: 3 articles (05/2003 - 08/2002)|
|7.||Artru, Alan A: 3 articles (05/2003 - 08/2002)|
|8.||Shapira, Yoram: 3 articles (05/2003 - 08/2002)|
|9.||Ongali, Brice: 2 articles (05/2006 - 12/2005)|
|10.||Marchand-Verrecchia, Catherine: 2 articles (05/2006 - 08/2003)|
|1.||Brain Edema (Cerebral Edema)
01/01/2000 - "No significant reduction of hemispheric brain swelling (+7.4 +/- 2.9%) was found in animals receiving high-dose LF16-0687 as compared to the untreated controls. "
09/01/2003 - "LF 16-0687 Ms given 30 min after injury reduced the neurological deficit by 26% and the cerebral edema by 22% when evaluated 4 h after CHT. "
11/01/2001 - "To examine the latter possibility we studied a surrogate condition for the earliest possible administration of LF 16-0687 Ms after CHT, e.g., we examined brain edema and NSS when LF 16-0687 Ms was given 15 min before CHT in rats. "
10/01/2001 - "Pretreatment with 10 microg/kg/min LF 16-0687 decreased brain swelling significantly to 6.4 +/- 1.3% (p < 0.05). "
01/01/2000 - "Currently it is studied whether LF16-0687 also reduces brain swelling when given after an insult."
|3.||Brain Injuries (Brain Injury)
01/01/2009 - "Adults with traumatic brain injury and a Glasgow Coma Scale score of 12 or less, who had a CT scan showing an intracranial abnormality consistent with trauma, and were within eight hours of their injury were randomly allocated to low, medium or high dose Anatibant or to placebo. "
01/01/2009 - "A response to and comment on The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Haleema Shakur, Ian Roberts, et al."
01/01/2009 - "Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury."
01/01/2009 - "The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury."
12/01/2005 - "A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury."
|4.||Closed Head Injuries
09/01/2003 - "Using the non-peptide B2R antagonist LF 16-0687 Ms and B2R null (B2R-/-) mice, we investigated the role of B2R in a model of closed head trauma (CHT). "
05/01/2006 - "Autoradiographic analysis of mouse brain kinin B1 and B2 receptors after closed head trauma and ability of Anatibant mesylate to cross the blood-brain barrier."
05/01/2003 - "LF 16-0687 Ms previously was reported to improve Neurological Severity Score (NSS) and decrease cerebral edema and prostaglandin E(2) (PGE(2)) release after closed head trauma (CHT) in rats. "
08/01/2002 - "LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats."
11/01/2001 - "Giving LF 16-0687 Ms (a bradykinin B2 receptor antagonist) 1 hour after closed head trauma (CHT) previously was reported to decrease brain edema at 24 hours and improve neurologic severity score (NSS) at 7 days. "
|5.||Wounds and Injuries (Trauma)
12/01/2005 - "Interestingly, plasma and CSF levels of BK1-5 were significantly and markedly increased after trauma (e.g., 34,700 +/- 35,300 fmol/mL in plasma vs. 34.9 +/- 5.6 fmol/mL previously reported for normal volunteers), supporting the use of Anatibant as a treatment of secondary brain damage. "
10/01/2001 - "Treatment with LF 16-0687 for 24 h (10 microg/kg/min) started 30 or 60 min after trauma did not reduce brain water content or hemispheric swelling. "
10/01/2001 - "Another three groups of animals (n = 10, each) received 10 microg/kg/min LF 16-0687 starting 30 or 60 min after trauma or vehicle (0.9% NaCl) for 24 h. "
01/01/2000 - "Animals of two experimental groups were receiving either LF16-0687 as high or low dose, whereas one group of untreated animals with trauma was treated with 0.9% NaCl as continuous infusion beginning 10 min before until 24 h after lesion. "
08/01/2002 - "In dose-effect studies, LF 16-0687 Ms doses of 0.75-4.5 mg/kg given 1 h after trauma significantly reduced the development of edema in the injured hemisphere by a maximum of 70%. "
|1.||2,5-dichloro-4-bromophenol (B 2)
|3.||Bradykinin B2 Receptor
|4.||Prostaglandins E (PGE)
|5.||N- (4'- fluorobutyrophenone)- 4- (4- chlorophenyl)pyridinium (HPP(+))
|10.||Nitric Oxide Synthase (NO Synthase)